- Home
- GSL vs ORIC Comparison
GSL vs ORIC Comparison
Compare GSL & ORIC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GSL
- ORIC
- Stock Information
- Founded
- GSL 2007
- ORIC 2014
- Country
- GSL Greece
- ORIC United States
- Employees
- GSL N/A
- ORIC N/A
- Industry
- GSL Marine Transportation
- ORIC Biotechnology: Pharmaceutical Preparations
- Sector
- GSL Consumer Discretionary
- ORIC Health Care
- Exchange
- GSL Nasdaq
- ORIC Nasdaq
- Market Cap
- GSL 753.1M
- ORIC 633.7M
- IPO Year
- GSL 2006
- ORIC 2020
- Fundamental
- Price
- GSL $21.23
- ORIC $8.21
- Analyst Decision
- GSL Strong Buy
- ORIC Strong Buy
- Analyst Count
- GSL 1
- ORIC 9
- Target Price
- GSL $29.00
- ORIC $18.75
- AVG Volume (30 Days)
- GSL 401.9K
- ORIC 331.7K
- Earning Date
- GSL 11-11-2024
- ORIC 11-12-2024
- Dividend Yield
- GSL 7.76%
- ORIC N/A
- EPS Growth
- GSL 7.30
- ORIC N/A
- EPS
- GSL 8.96
- ORIC N/A
- Revenue
- GSL $701,476,000.00
- ORIC N/A
- Revenue This Year
- GSL $6.45
- ORIC N/A
- Revenue Next Year
- GSL N/A
- ORIC N/A
- P/E Ratio
- GSL $2.37
- ORIC N/A
- Revenue Growth
- GSL 8.60
- ORIC N/A
- 52 Week Low
- GSL $18.75
- ORIC $6.33
- 52 Week High
- GSL $30.32
- ORIC $16.65
- Technical
- Relative Strength Index (RSI)
- GSL 34.07
- ORIC 40.22
- Support Level
- GSL $21.10
- ORIC $7.41
- Resistance Level
- GSL $21.89
- ORIC $8.42
- Average True Range (ATR)
- GSL 0.60
- ORIC 0.56
- MACD
- GSL 0.00
- ORIC -0.16
- Stochastic Oscillator
- GSL 16.18
- ORIC 28.57
About GSL Global Ship Lease Inc New
Global Ship Lease Inc operates in the container shipping industry. The company owns and charters out containerships under long-term, fixed-rate charters to container liner companies. The majority of the company's revenues are derived from charters to MAERSK. Its fleet consisted of more than 60 containerships.
About ORIC Oric Pharmaceuticals Inc.
ORIC Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It has a pipeline of therapies designed to counter resistance mechanisms in cancer by leveraging its expertise within three specific areas: hormone-dependent cancers, precision oncology, and key tumor dependencies. The company has product candidates namely ORIC-944, ORIC-114, and ORIC-533.